Sweden's Medivir to sell generics unit; PharMerica adopts poison pill after Omnicare offer;

@FiercePharma: Merck's discount offer to NICE wins OK for anti-TNF drug Simponi. Piece | Follow @FiercePharma

> Sweden's Medivir agreed to sell a generics subsidiary BMM Pharma, acquired in its BioPhausia buyout earlier this year, to Bluefish Pharmaceuticals for 38 million krona in cash and inventory, or about $9 million. Medivir release

> PharMerica adopted a poison pill to ward off hostile takeovers after receiving a $441 million bid from larger rival Omnicare ($OCR) earlier this week. Item

> AstraZeneca ($AZN) bought more than 1 million shares for 2826 pence per share as part of its ongoing buyback program. News

> Hi-Tech Pharmacal acquired marketing rights to an ANDA from KVK-Tech for an allergy drug to be marketed under the Lodrane brand name. Hi-Tech release

> UBS cut its target price for Hikma to 850 pence after first half earnings failed to live up to forecasts. Article

Biotech News

@FierceBiotech: Report: Samsung to test genomic analysis service. Item | Follow @FierceBiotech

@JohnCFierce: FDA approves Firazyr (Shire) for HAE. News | Follow @JohnCFierce

@RyanMFierce: Furiex Pharmaceuticals snags $15M loan to advance pipeline, including antibiotic, IBC drug and statin Article | Follow @RyanMFierce

@MaureenFierce: CDC: Teen HPV vaccination rates lagging. Article | Follow @MaureenFierce

> Study: Cancer trial participation less than 1%. Report

> J&J's XR pain drug gets FDA nod. Piece

> Gene therapy breaks 'bubble boy disease.' Article

> Medivir deals generics biz amid HepC drug trials. More

And Finally... The cost of treating obesity and related diseases is expected to add 2% to healthcare bills in the U.S. and U.K. by 2030. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.